Response to “the flexible therapeutic approach to the BCLC B stage”: time for scoring systems?
We have read with interest the review by Galle et al concerning the therapeutic strategy in intermediate stage hepatocellular carcinoma (HCC)[1]. The heterogeneity of this group is highlighted, whereas only transarterial chemoembolization (TACE) is recommended in the guidelines. However, some (Barcelona Clinic Liver Cancer) BCLC B patients may not benefit from TACE. Thus, in this review other therapeutic approaches are discussed, based on a very exhaustive review of the literature, from transplantation to the most recent systemic treatments such as immunotherapy.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Xavier Adhoute, Guillaume P énaranda, Floriane Sellier, Jean-Luc Raoul Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Gastroenterology | Hepatocellular Carcinoma | Immunotherapy | Liver | Liver Cancer | Liver Transplant | Transplants | Urology & Nephrology